FDG PET/CT扫描对Ki67指数≤5%的高分化神经内分泌肿瘤管理改变的影响
该回顾性观察研究纳入63例Ki67指数≤5%的高分化神经内分泌肿瘤患者,同时行FDG PET与生长抑素受体PET(68Ga-DOTANOC PET)。FDG PET阳性占39.6%、弱阳性占17.4%、阴性占42.8%;FDG PET/CT导致17.4%的患者管理改变。有明确临床指征行FDG PET者中FDG阳性或弱阳性比例高于无指征者。
要点
- Ki67≤5%的高分化NET中FDG PET阳性者占39.6%,弱阳性占17.4%。
- FDG PET/CT使17.4%患者管理改变,1级9.6%、2级25%。
- 有明确FDG PET临床指征者阳性或弱阳性比例高于无指征者(P=0.004)。
核心结论
- 在低级别NET中,相当数量病例出现FDG阳性,并导致17.4%的病例管理改变。
- 特定临床特征可用于区分低级别NET中FDG亲和与非亲和病变,并对管理改变产生影响。
研究设计与样本
- 回顾性观察研究,纳入63例Ki67指数≤5%且同时行FDG PET与生长抑素受体PET(68Ga-DOTANOC PET)的NET病例。
主要发现
- 60例原发灶和(如存在)转移灶显示强烈SSTR表达;3例无SSTR表达证据,其扫描在原发肿瘤切除后进行。
- FDG PET阳性25例(39.6%)、弱阳性11例(17.4%)、阴性27例(42.8%)。
- 34例有明确FDG PET临床原因,其中73.5%为FDG阳性或弱阳性、26.5%为阴性;其余29例无正当理由或特定指征,其中62.1%为FDG阴性、37.9%为阳性(P=0.004)。
- 未治疗且症状持续时间≤5个月的患者FDG阳性率高于症状持续时间>5个月者(P=0.006)。
- FDG PET/CT导致全部患者中17.4%管理改变,1级患者中9.6%、2级患者中25%。
关键数值与推荐
- FDG PET按视觉量表分为阳性、弱阳性和阴性。
- 加用化疗被视为FDG导向的治疗改变。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: This study aimed to see the impact of FDG PET/CT with somatostatin receptor PET (SSTR PET) in directing the treatment plan in lower-grade well-differentiated neuroendocrine tumors (NETs) with Ki67 index ≤5%. METHODS: Sixty-three NET cases with Ki67 index ≤5% with both FDG PET and SSTR PET ( 68 Ga-DOTANOC PET) were included for this retrospective observational study. FDG PET findings were classified into positive, weakly positive, and negative based on a visual scale. Clinical factors considered while referring for FDG PET scan were audited from electronic medical records. The addition of chemotherapy was considered as FDG-directed change in treatment. RESULTS: Sixty patients showed intense SSTR expression in the primary and metastatic sites (if present). Three patients showed no evidence of SSTR expression, in whom the scans were done after resection of the primary tumor. The FDG PET was positive in 25 (39.6%), weakly positive in 11 (17.4%), and negative in 27 (42.8%). Specific clinical reason for doing FDG PET was found in 34 patients, and in the remaining 29, there was no justification or specific indication for doing the FDG study; 73.5% of patients from the former group was either FDG positive or weakly positive, and 26.5% were negative; in the other group, 62.1% were FDG-negative, and 37.9% were positive ( P = 0.004). Treatment-naive patients with symptom duration of ≤5 months were associated with more FDG positivity than patients with >5 months' symptom duration ( P = 0.006). FDG PET/CT led to change in management in 17.4% of all the patients, 9.6% of grade 1, and 25% of grade 2 patients. CONCLUSIONS: In lower-grade NET, FDG positivity was seen in a sizable number of the cases, and this led to change in management in 17.4% of the cases. Specific clinical features could be utilized to successfully discriminate between FDG-avid and non-FDG-avid disease in lower-grade NETs, and this had impact in management change as well.
引用
- Choudhury S, Agrawal A, Rangarajan V, et al. Impact of FDG PET/CT Scan in Changing Management of Well-Differentiated Neuroendocrine Tumors With Ki67 Index Less Than or Equal to 5. Clin Nucl Med. 2022. PMID: 36215398. doi:10.1097/RLU.0000000000004365
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。